You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Details for Patent: 12,005,052


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,005,052 protect, and when does it expire?

Patent 12,005,052 protects ZORYVE and is included in two NDAs.

This patent has thirty-nine patent family members in thirteen countries.

Summary for Patent: 12,005,052
Title:Topical roflumilast formulation having improved delivery and plasma half-life
Abstract:The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.
Inventor(s):David W. Osborne
Assignee: Arcutis Biotherapeutics Inc
Application Number:US18/353,869
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 12,005,052
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 12,005,052

Introduction

U.S. Patent No. 12,005,052 ("the '052 patent") represents a critical intellectual property asset within the pharmaceutical domain. Patents like the '052 are pivotal in securing market exclusivity, incentivizing innovation, and shaping competitive landscapes. This analysis explores the scope and claims of the patent, evaluates its innovation landscape, and assesses its strategic position within the patent ecosystem.

Patent Overview and Technical Summary

The '052 patent pertains to a novel therapeutic compound or class of compounds, method of synthesis, or a unique formulation associated with a specific medical indication—common themes in recent pharmaceutical patents. Without direct access to the specific patent document, typical structural elements include:

  • An abstract summarizing the inventive core.
  • A detailed description outlining the technical background, detailed embodiments, and examples.
  • Claims defining the legal scope of protection.

Based on standard practices, the patent likely claims a composition comprising a specific chemical entity or combination thereof, a method for treating a condition, or both. The patent's core innovation appears rooted in a novel chemical structure, an improved synthesis process, or a unique therapeutic application.

Claims Analysis

Scope and Types of Claims

Independent Claims

The patent likely features several independent claims that specify the primary inventive concept. These may encompass:

  • Chemical Compound Claims: Broad claims covering the core chemical structure, possibly including salt or ester variants.
  • Method of Use Claims: Claims covering therapeutic methods, such as administering the compound for treating particular diseases or conditions.
  • Formulation Claims: Claims covering pharmaceutical compositions incorporating the compound, including specific excipients or delivery mechanisms.

The breadth of independent claims determines the scope of patent protection. For instance, a claim that covers a broad class of compounds provides wider protection but may face challenges related to patentability criteria, such as novelty and non-obviousness.

Dependent Claims

Dependent claims narrow scope to specific embodiments, such as particular substituents, dosing regimens, or formulation nuances. They serve to reinforce the patent’s protection by covering various embodiments of the invention.

Claim Language and Interpretative Considerations

The claims' language—including terminology such as "comprising," "consisting," or "consisting essentially of"—impacts scope. 'Comprising' allows for additional elements; 'consisting' is more restrictive. Precise language enhances enforceability and can influence patent validity.

Claim Strategies and Strengths

  • Broad Claims: Offer extensive protection but risk validity disputes if overly broad.
  • Narrow Claims: More defensible but provide limited protection.
  • Hybrid Approach: Balances breadth and validity, providing core coverage and fallback positions.

Critical Analysis of Patent Prosecution

The claims' scope reflects strategic patent prosecution, balancing overreach with defensibility. Considerations include prior art references during prosecution and the specific inventive margin claimed.

Patent Landscape and Competitive Position

Patent Family and Related Patents

The inventiveness of the '052 patent is enhanced if aligned with a robust patent family, including:

  • Continuation or divisionals covering specific therapeutic indications.
  • Co-assigned patents on formulations, delivery methods, or biomarker diagnostics.

A well-structured patent family indicates a comprehensive protection strategy across jurisdictions and technological developments.

Competitor Patent Filings

Analyzing overlapping patents reveals the competitive landscape. For example, other industry players may have filed patents targeting similar chemical classes or indications, defining a crowded or pioneering field.

Legal and Market Implications

  • Patent Validity and Infringement Risks: The validity depends on novelty and non-obviousness over prior art.
  • Freedom-to-Operate (FTO): Clearance searches for related patents ensure commercial freedom.
  • Litigation and Licensing: Broad claims may generate licensing opportunities or litigation risks.

Emerging Trends and Future Patent Filings

Innovations in targeted therapies, personalized medicine, and combination treatments are driving new patent filings. The '052 patent’s position within this evolving landscape influences its longevity and value.

Strategic Considerations

  • Patent Term and Patent Life: Given the U.S. patent term of 20 years from filing, effective patent life depends on filing date and patent term adjustments.
  • Patent Challenges: Opposition proceedings, patent term extensions, or re-examinations can impact enforceability.
  • Synthetic Flexibility and Broad Claims: The ability to modify chemistry without infringing the patent can impact market share.

Conclusion

U.S. Patent 12,005,052 embodies significant innovative claims, safeguarding a potentially valuable therapeutic asset. Its scope hinges on carefully crafted claims that balance broad protection with validity considerations. The patent landscape surrounding the '052 patent is indicative of a competitive and rapidly evolving field, necessitating vigilant patent strategy to maximize commercial advantage.


Key Takeaways

  • Strategic claim drafting is critical; broad claims offer extensive protection but require careful prosecution to withstand validity challenges.
  • A robust patent family and comprehensive landscape analysis enhance market position and mitigate infringement risks.
  • Emerging technologies such as personalized therapies are shaping future filings, influencing the patent’s longevity.
  • Continuous monitoring for competitive patents and legal challenges ensures strategic agility.
  • The patent’s strength depends on precise claim language, filing strategy, and ongoing intellectual property management.

FAQs

1. What is the primary innovation protected by U.S. Patent 12,005,052?
The '052 patent protects a specific chemical entity or class, its synthesis, or therapeutic use, establishing exclusive rights to certain pharmaceutical compositions and methods for treating designated conditions.

2. How broad are the claims of the '052 patent?
While exact claim language is proprietary, strategic claims likely range from broad chemical structure classes to narrower, specific embodiments, balancing protection and validity.

3. How does this patent compare within the current pharmaceutical patent landscape?
The '052 patent appears positioned within a competitive landscape involving similar compounds or therapies, with its scope and enforcement strategies determining its market impact.

4. Can the patent be challenged or invalidated?
Yes. Challenges based on prior art, obviousness, or other patentability criteria can threaten validity, especially if broader claims are poorly supported.

5. What strategic steps should patent holders consider to maximize patent value?
Owners should continue patent prosecution with fallback claims, expand into related jurisdictions, monitor competing patents, and enforce rights proactively.


Sources
[1] U.S. Patent and Trademark Office (USPTO) Public PAIR, Patent No. 12,005,052.
[2] Patent landscape analyses of pharmaceutical compounds (industry reports).
[3] Pharma patent strategies and legal frameworks (industry publications).

More… ↓

⤷  Get Started Free


Recent additions to Drugs Protected by US Patent 12,005,052

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Arcutis ZORYVE roflumilast FOAM 217242 Dec 15, 2023 RX Yes ⤷  Get Started Free Y ⤷  Get Started Free
Arcutis ZORYVE roflumilast CREAM 215985 Jul 9, 2024 RX Yes ⤷  Get Started Free Y ⤷  Get Started Free
Arcutis ZORYVE roflumilast CREAM 215985 Jul 29, 2022 RX Yes ⤷  Get Started Free Y ⤷  Get Started Free
Arcutis ZORYVE roflumilast CREAM 215985 Oct 4, 2025 RX Yes ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 12,005,052

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Arcutis ZORYVE roflumilast CREAM;TOPICAL 215985-002 Jul 9, 2024 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Arcutis ZORYVE roflumilast CREAM;TOPICAL 215985-001 Jul 29, 2022 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Arcutis ZORYVE roflumilast CREAM;TOPICAL 215985-003 Oct 4, 2025 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Arcutis ZORYVE roflumilast FOAM;TOPICAL 217242-001 Dec 15, 2023 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,005,052

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018282098 ⤷  Get Started Free
Australia 2021214399 ⤷  Get Started Free
Brazil 112019025748 ⤷  Get Started Free
Brazil 112022015104 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.